Hengrui Medicine: Received Four Drug Clinical Trial Approval Notices.

Hengrui Pharmaceuticals announced that the company and its subsidiaries have received approval from the National Medical Products Administration for the clinical trial approval of SHR-8068 injection, atezolizumab injection, bevacizumab injection, and apatinib mesylate tablets. The company will soon conduct clinical trials. SHR-8068 injection is a fully human anti-CTLA-4 monoclonal antibody, atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody developed independently, bevacizumab injection is a humanized anti-VEGF monoclonal antibody, and apatinib mesylate tablets are innovative small molecule targeted drugs. The research and development investments for these drugs are approximately 2.14 billion yuan for SHR-8068 injection, 8.87 billion yuan for atezolizumab injection, 3.45 billion yuan for bevacizumab injection, and 5.87 billion yuan for apatinib mesylate tablets. According to relevant laws and regulations, after obtaining the clinical trial approval notification, clinical trials must be conducted and approved by the National Medical Products Administration before production and marketing can occur.